Rezolute Inc

Rezolute’s stock plunged after a failed lead asset trial, exposing financial distress amid hopes to develop metabolic and orphan disease therapies.

Rezolute’s stock drops 85% after a failed Phase 3 study and Block & Leviton’s investigation; analysts split on future prospects and investors weigh potential recovery.

Rezolute Inc. rebounds on Nasdaq, targeting metabolic and orphan‑disease therapies with global reach—watch its growth, market cap, and R&D strategy.

Rezolute, Inc. is a late-stage rare disease company making significant strides in addressing critical health challenges associated with hypoglycemia and diabetic macular edema through its innovative therapeutic candidates, Ersodetug and RZ402.

Rezolute Inc. has navigated a financial rollercoaster with a $90 million stock offering, while making promising progress in its clinical trials for its lead asset Ersodetug, a treatment for hypoglycemia caused by hyperinsulinism.